Esomeprazole inhibits proliferation of scleroderma fibroblasts via cell cycle regulation
These results suggest that esomeprazole induces G1 phase arrest by upregulating p21 and downregulating CDK1 and CDK2, thereby inhibiting fibroblast proliferation. These data provide important insights into how esomeprazole regulates fibroblast proliferation in scleroderma and suggest that it may represent a potential therapeutic intervention.
Authors
- Manisha Ahir (ORCID: https://orcid.org/0000-0001-9647-6844)
- Maureen D. Mayes (ORCID: https://orcid.org/0000-0001-5070-2535)
- David R. Gius (ORCID: https://orcid.org/0000-0001-9647-3571)
- Anil Goud Jegga (ORCID: https://orcid.org/0000-0002-4881-7752)
- Mark Bonnen
- Sydney B. Montesi (ORCID: https://orcid.org/0000-0002-5724-6808)
- Mohammad Aasif Khan
- Yohannes T. Ghebre
- Shaheer Koniyan
- Justin Leung
Institutions
- Tufts University (US)
- Cincinnati Children's Hospital Medical Center (US)
- The University of Texas at San Antonio Health Science Center (US)
- Baylor College of Medicine (US)
- Massachusetts General Hospital (US)
- Longevity Biotech (United States) (US)
- The University of Texas Health Science Center (US)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2026-01-06
- DOI
- https://doi.org/10.3389/fphar.2025.1703115
- Primary Topic
- Systemic Sclerosis and Related Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Cancer Prevention and Research Institute of Texas
- National Institutes of Health
- National Heart, Lung, and Blood Institute
- National Cancer Institute
- National Institute of General Medical Sciences